Currently out of the existing stock ratings of Robbie Marcus, 161 are a BUY (63.64%), 77 are a HOLD (30.43%), 15 are a SELL (5.93%).

Robbie Marcus

Work Performance Price Targets & Ratings Chart

Analyst Robbie Marcus, carries an average stock price target met ratio of 61.91% that have a potential upside of 19.17% achieved within 144 days. Previously, Robbie Marcus worked at JPMORGAN.

Robbie Marcus’s has documented 478 price targets and ratings displayed on 36 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on NPCE, Neuropace at 14-May-2025.

Wall Street Analyst Robbie Marcus

Analyst best performing recommendations are on CVRX (CVRX).
The best stock recommendation documented was for INGN (INOGEN) at 5/8/2019. The price target of $72 was fulfilled within 1 day with a profit of $4.21 (6.21%) receiving and performance score of 62.1.

Average potential price target upside

of $43.22 (11.52%) on ISRG (INTUITIVE SURGICAL).
of $39.2 (18.06%) on PEN (PENUMBRA).
of $37.19 (19.85%) on PODD (INSULET).

AFIB Acutus Medical DXCM DexCom GKOS Glaukos Corp INGN Inogen IRTC iRhythm Technologies MDT Medtronic PLC SDC SmileDirectClub IART Integra LifeSciences Holdings PEN Penumbra EAR Eargo RXST Rxsight SYK Stryker TMCI Treace Medical Concepts ABT Abbott Laboratories ATRC AtriCure BAX Baxter International BDX Becton Dickinson and Company BVS Bioventus EW Edwards Lifesciences Corp IRT Independence Realty Trust UTRS Minerva Surgical BLCO Bausch + Lomb Corp ZBH Zimmer Biomet Holdings BSX Boston Scientific Corp COO The Cooper Companies Common Stock INSP Inspire Medical Systems ISRG Intuitive Surgical NVRO Nevro Corp PODD Insulet SILK Silk Road Medical XENT Intersect ENT CNMD CONMED CVRX CVRx NPCE Neuropace ZIMV ZimVie ENOV Enovis Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

William Plovanic (CANACCORD)